TRT Monitoring Guide: What Labs to Run and When (2026)

Executive Summary

Most men starting testosterone replacement therapy spend their energy getting the prescription. The smarter focus is the monitoring protocol — the blood work that tells you whether TRT is working, whether it is safe, and whether you need to adjust. Poorly monitored TRT is how men end up with undetected polycythemia, crashed estradiol, or a PSA spike that went unnoticed for a year. A well-monitored protocol is the difference between informed optimization and flying blind.

The good news: the core TRT monitoring panel is not complex. A handful of markers — testosterone levels, estradiol, hematocrit, PSA, and a metabolic panel — cover the vast majority of clinically meaningful variables. The nuance is in the timing (when to draw relative to your last injection or dose), the schedule (how often each marker needs checking), and the thresholds (which numbers require immediate action versus watchful adjustment). This guide consolidates all of that into one canonical reference. For context on reading your lab results, see how to read testosterone lab results. For the complete TRT protocol framework, see how to build a TRT protocol.

This guide follows AUA 2022 guidelines, Endocrine Society clinical practice guidelines, and the post-TRAVERSE evidence base for monitoring intervals and thresholds. It applies to the most common TRT forms — injectable testosterone cypionate/enanthate, transdermal gels/creams, and oral TRT (Kyzatrex/Jatenzo). Where monitoring differs meaningfully between delivery routes, those differences are noted.

At-a-Glance Comparison

TRT blood work schedule and target ranges. Based on AUA 2022 guidelines, Endocrine Society clinical practice guidelines, and TRAVERSE 2023. Updated March 2026.

The pre-TRT baseline workup: what to test before your first dose

The baseline lab panel before starting TRT is the most clinically important set of results you will ever have — it proves hypogonadism, rules out contraindications, and sets the reference points for all future monitoring. Buyers searching for trt labs usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The AUA 2022 guideline and Endocrine Society framework require a specific workup before TRT can be appropriately initiated. Many telehealth platforms skip parts of this to accelerate prescription — which creates gaps in your monitoring baseline and may result in treating symptoms that have a different cause.

Required baseline labs (non-negotiable):
1. Total testosterone × 2 — two separate morning draws (7–10 AM) on different days, both ≤300 ng/dL to confirm hypogonadism. One low reading is not sufficient for diagnosis. Morning draws matter because testosterone follows a diurnal pattern: levels are highest in the morning and drop 20–35% by late afternoon.
2. CBC (complete blood count) — hematocrit baseline before TRT; rules out pre-existing polycythemia that would complicate monitoring
3. PSA — required for men ≥40; documents your pre-TRT PSA so future rises can be assessed against a known starting point, not estimated
4. Comprehensive metabolic panel (CMP) — liver function (ALT, AST), kidney function (creatinine), and glucose; especially important if considering oral TRT
5. Lipid panel — baseline cardiovascular risk documentation; TRT modestly affects HDL

Strongly recommended baseline labs:
6. LH and FSH — determine hypogonadism type (primary vs secondary); low LH+low T = secondary (potentially reversible with enclomiphene); high LH+low T = primary (testicular failure, TRT or exogenous approach needed). For detailed explanation, see primary vs secondary hypogonadism.
7. Estradiol (sensitive assay) — baseline E2 helps interpret post-TRT estradiol levels and determines your starting aromatization rate
8. SHBG (sex hormone-binding globulin) — required to interpret free testosterone, especially for men with borderline total T (250–350 ng/dL)
9. Free testosterone (calculated or direct) — if total T is borderline and SHBG is known to be high or low

Consider at baseline (situational):
10. Prolactin — if secondary hypogonadism is suspected, prolactinoma should be ruled out (elevated prolactin suppresses LH/FSH)
11. Thyroid panel (TSH ± free T4) — thyroid dysfunction causes fatigue and libido symptoms that overlap with low T; treating thyroid first may resolve symptoms without TRT
12. Iron studies (ferritin, serum iron) — if anemia is suspected or hematocrit is low at baseline
13. Bone mineral density (DEXA) — strongly recommended for men ≥50 with low T, or any man with long-standing hypogonadism who may have silent bone loss. See TRT and bone density for the full bone monitoring framework. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: telehealth TRT platforms that prescribe after a single total testosterone measurement, no LH/FSH, and no PSA baseline — leaving men with no reference point for future PSA monitoring and potentially treating secondary hypogonadism that was reversible with clomiphene or lifestyle modification instead of lifelong TRT. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

The 3-month follow-up: the most important labs on TRT and why injection timing matters

The 3-month mark is the most clinically sensitive point in any TRT protocol — hematocrit has risen meaningfully, estradiol has changed, and your testosterone level can be accurately assessed for the first time. Getting the draw timing right is as important as which markers you test. Buyers searching for trt labs usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The first follow-up panel at 3 months should include: total testosterone, estradiol (sensitive), CBC/hematocrit, PSA, and a symptom review. This is the optimization window — most dose adjustments happen based on 3-month data, and most early side effect signals appear here first.

Critical: injection timing for your blood draw

For men on injectable TRT (testosterone cypionate or enanthate), the timing of your blood draw relative to your last injection has an enormous effect on your measured testosterone level:

— Peak draw (24–48 hours post-injection): shows your highest testosterone level; useful for ruling out supraphysiologic peaks but does not represent your average level
— Trough draw (just before your next injection): shows your lowest level; useful for confirming your minimum is adequate (≥300 ng/dL trough is a common goal), but does not represent your average either
— Mid-cycle draw (halfway between injections): the closest approximation to your average testosterone level; most useful for dose-optimization decisions

Standard clinical practice for injections: Draw at trough (just before your next scheduled injection) for the first optimization assessment. This confirms your trough is above minimum hypogonadal threshold (≥300 ng/dL). A trough <300 ng/dL on a weekly injection protocol suggests dose increase or frequency increase is needed.

For transdermal TRT (gels/creams): Draw 2–4 hours after application, at the same time of day consistently. Gels and creams produce more stable levels than injections, but draw timing still matters — testing too early or too late gives inaccurate results.

For oral TRT (Kyzatrex, Jatenzo): Draw 4–6 hours post-dose at the same mealtime consistently. Oral TRT is highly food-dependent; draws not consistent with eating pattern will not reflect therapeutic levels accurately. Liver enzyme monitoring (ALT/AST) should be added to the 3–6 month panel for oral TRT.

Estradiol at 3 months: Estradiol rises proportionally with testosterone on TRT — most men see E2 increase to 25–50 pg/mL on therapeutic testosterone levels. This is expected and usually appropriate. The key question at 3 months is whether any symptoms (gynecomastia, water retention, mood changes, reduced libido) are E2-driven. For the full estradiol management framework, see anastrozole on TRT.

Hematocrit at 3 months: This is the highest-risk window for erythrocytosis — hematocrit rises fastest in the first 3 months of TRT. A hematocrit above 52–53% at 3 months warrants close monitoring; above 54% requires dose reduction before the 6-month mark. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: men drawing blood at peak (24 hours post-injection) instead of trough, getting a falsely high testosterone reading (e.g., 1,200 ng/dL when their average is 650 ng/dL), and having their dose reduced unnecessarily — or drawing at the wrong time and having their protocol adjusted based on a number that doesn't represent their actual levels. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Core ongoing monitoring: the annual maintenance panel and 6-month checks

Once your protocol is optimized and stable, TRT monitoring shifts from frequent optimization to annual safety surveillance — with specific triggers for more frequent testing. Buyers searching for trt labs usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

For stable, well-optimized TRT (levels in range, no concerning trends, no dose changes), the Endocrine Society and AUA guidelines converge on an annual monitoring rhythm after the first 6–12 months:

Annual minimum panel:
1. Total testosterone (trough draw, injection protocol)
2. Estradiol (sensitive)
3. CBC / hematocrit
4. PSA (especially if ≥45 or any prior PSA elevation)
5. Lipid panel
6. CMP (ALT, AST, creatinine, glucose)

Consider every 6 months if:
— Hematocrit previously exceeded 52% and is being watched
— PSA has shown any trend toward elevation
— Protocol includes anastrozole (E2 monitoring every 6 months to prevent over-suppression)
— Protocol was adjusted in the past 6 months (recheck 4–6 weeks after any change, then at next scheduled interval)
— On oral TRT (liver enzyme monitoring typically more frequent in first year)

After any protocol change:
The rule of thumb: recheck testosterone (and estradiol if relevant) 4–6 weeks after any dose change, injection frequency change, or delivery method change. Testosterone levels do not reach new steady state immediately — especially for injections, which take 4–5 half-lives to stabilize. Acting on a measurement taken 1 week after a dose change will produce unreliable data.

What does NOT need annual rechecking on stable TRT:
— LH and FSH: these are suppressed to near-zero on exogenous TRT — rechecking adds no clinical value and wastes money
— Prolactin: once ruled out at baseline, rechecking is not indicated unless new symptoms emerge (galactorrhea, severe headache, new visual changes)
— Thyroid panel: not TRT-specific; follow standard primary care thyroid screening guidelines

DEXA and bone monitoring:
For men on anastrozole, with pre-existing low bone density, or who have been hypogonadal for many years: DEXA at baseline and every 1–2 years on TRT. For most men without bone risk factors, standard bone screening guidelines apply (typically DEXA at 70+, or earlier with risk factors). See TRT and bone density for the full monitoring framework. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: men who stop monitoring after their first year of TRT because they 'feel fine' — missing gradually rising hematocrit, a PSA trend, or estradiol drift that became problematic without any acute symptoms. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Red flag thresholds: numbers that require immediate clinical action

Most TRT monitoring involves gradual optimization. But a handful of lab values require prompt action — not 'mention it at your next annual visit.' Understanding these thresholds prevents the cases where delayed response turns a manageable finding into a clinical problem. Buyers searching for trt labs usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The following thresholds are based on AUA 2022, Endocrine Society, FDA label requirements, and post-TRAVERSE safety guidance.

Hematocrit red flags:
— Hematocrit 52–54%: Yellow flag. Dose reduction consideration; more frequent monitoring. Reduce injection peaks if on every-2-week protocol (switch to weekly).
— Hematocrit ≥54%: Red flag. AUA/Endocrine Society action threshold. Dose reduction is first-line. If dose reduction does not resolve: therapeutic phlebotomy. If still uncontrolled: TRT discontinuation. Do not ignore — polycythemia at this level meaningfully increases VTE risk. See TRT and blood donation for phlebotomy options.
— Hematocrit ≥58%: Urgent. Requires prompt clinical evaluation for secondary polycythemia.

PSA red flags:
— PSA rise >1.4 ng/mL in any 12-month period: Urology referral required, per AUA guidelines. This is the most important PSA metric on TRT — trajectory matters more than absolute value.
— PSA >4.0 ng/mL at any point: Urology workup. The pre-TRT baseline makes this actionable — if your baseline was 1.2 and you are now at 4.1, that is a 2.9 ng/mL rise, which requires evaluation regardless of whether 4.0 is the raw threshold.
— First-3-month PSA rise >0.5 ng/mL: Warrants re-evaluation before continuing TRT. A rise of 0.3–0.5 ng/mL in the first 3–6 months is expected and benign (baseline diagnostic effect); a larger jump early on is not. See TRT and prostate for the full PSA framework.

Testosterone level red flags:
— Total T >1100 ng/dL (trough for injections, or any draw for stable-release methods): Overdose signal. Reduce dose or frequency. Supraphysiologic testosterone is associated with greater erythrocytosis and cardiovascular risk without additional symptom benefit for most men.
— Total T <250 ng/dL at trough: Under-dosed. Dose increase or frequency increase (weekly vs biweekly) needed.

Estradiol red flags:
— E2 <15 pg/mL on TRT: Estrogen-deficient. Especially dangerous if on anastrozole. Associated with joint pain, poor bone remodeling, libido loss, and mood disruption. Review anastrozole dosing immediately.
— E2 persistently >80 pg/mL with symptoms: Dose adjustment consideration; avoid jumping to anastrozole unless symptoms persist after optimizing injection frequency.

Liver enzyme red flags (oral TRT):
— ALT or AST >3× upper limit of normal: Hold oral TRT, investigate. This threshold is the standard hepatotoxicity action threshold for oral medications affecting liver metabolism. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: providers who receive labs showing hematocrit 55% and schedule a follow-up in 3 months rather than taking immediate action — giving erythrocytosis time to compound before intervention while the patient has elevated thrombosis risk. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Lab timing for injections: how to draw blood for accurate results

The single most common source of misleading TRT lab results is wrong draw timing relative to the injection. A testosterone measurement is only interpretable if you know where in the injection cycle it was taken. Buyers searching for trt labs usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Testosterone from injectable esters (cypionate or enanthate) does not produce a flat blood level. It follows a curve: a peak 24–48 hours post-injection, a gradual decline, and a trough just before the next dose. The amplitude of this curve depends on injection frequency.

Weekly injection protocol (most common):
— Peak (24–48 hours post-injection): can reach 900–1,200 ng/dL
— Trough (6–7 days post-injection, just before next dose): typically 400–600 ng/dL
— Mid-cycle (3–4 days post-injection): roughly 600–800 ng/dL
— Recommendation: draw at trough for primary optimization assessment

Every-2-week injection protocol:
— Peak (24–48 hours): can reach 1,200–1,800+ ng/dL in some men
— Trough (13–14 days post-injection): can drop to 200–350 ng/dL (often sub-therapeutic)
— The wide amplitude is why q2w protocols produce more symptom cycling and more erythrocytosis
— Recommendation: draw at mid-cycle (7 days post-injection) for q2w protocols

Why trough-based draw is the standard:
Trough testing answers the most clinically important question: is my minimum level above the hypogonadal threshold? If your trough is ≥300 ng/dL (most clinicians target ≥350–400 ng/dL), your protocol maintains therapeutic levels throughout the cycle. A trough above 300 ng/dL combined with a mid-cycle estimated in the therapeutic range is sufficient for most men to confirm adequate dosing.

For SubQ injections: The same timing rules apply. SubQ and IM injections have similar pharmacokinetics with cypionate/enanthate — absorption rates differ minimally between routes at standard TRT doses. For delivery method comparison, see subcutaneous vs intramuscular TRT.

For transdermal (gel/cream):
Draw 2–4 hours post-application (the absorption peak window). Draw at the same time of day, on the same day of your application routine, every visit. Morning application + 2-hour draw is the most common and reproducible protocol.

For scrotal cream:
Draw 4–6 hours post-application. Scrotal cream absorbs faster and to higher DHT levels than standard topical; the draw window is shifted slightly later. Note: scrotal cream significantly elevates DHT — relevant context for men concerned about hair loss. See testosterone and hair loss.

For oral TRT (Kyzatrex/Jatenzo):
Draw 4–6 hours post-dose, taken with a fat-containing meal. Oral TRT is highly food-dependent — a high-fat meal increases peak absorption significantly. Confirm meal size/composition was similar between monitoring draws for comparability. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: a man on weekly injections draws at peak (36 hours post-injection), sees 1,050 ng/dL, gets told he is 'too high,' has his dose reduced, and then feels terrible for weeks because his trough drops to 200 ng/dL — when the original protocol was actually fine and the draw timing was the problem. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

DIY labs vs provider-included labs: how to get blood work without breaking the bank

Lab costs are one of the hidden expenses of TRT — and they vary enormously depending on your provider model, insurance coverage, and whether you use direct-to-consumer lab services. Buyers searching for trt labs usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

TRT monitoring labs can be obtained through three paths, each with different cost and convenience profiles.

Path 1: Provider-included lab programs
Many TRT telehealth clinics include lab work in their subscription fee — meaning you pay one monthly or quarterly cost that covers both the prescription and monitoring labs. This is the most convenient model and eliminates surprise lab bills.
— Marek Health and Defy Medical: specialist clinics that include comprehensive lab monitoring; tend to run more complete panels
— Maximus: includes quarterly labs in subscription model
— Roman and Hims: may offer labs but often require additional fees or use partner labs with variable cost
Before signing up with any provider, ask: What labs are included, at what frequency, and what is the out-of-pocket cost if I need additional panels?

Path 2: Direct-to-consumer lab ordering (DIY)
You can order your own blood work without a doctor's order through services like:
— LabCorp on Demand: order online, pay at checkout, draw at any LabCorp location
— Ulta Lab Tests: competitive pricing on TRT monitoring panels; can bundle markers
— Request A Test: similar to Ulta, with custom panel building
— Walk-In Lab: aggregates LabCorp and Quest capacity

Approximate DTC costs (2026):
— Total testosterone: $30–$70
— Estradiol (sensitive): $50–$100 (sensitive LC-MS/MS assay costs more than standard immunoassay)
— CBC: $15–$30
— PSA: $25–$50
— Comprehensive metabolic panel: $25–$45
— SHBG + free T: $60–$120
— Full TRT monitoring panel (bundled): $150–$300

Path 3: Insurance + PCP
If your primary care provider manages your TRT (or co-manages with a telehealth clinic), insurance may cover most monitoring labs under standard care codes. This is the lowest out-of-pocket option if you have decent insurance, but requires a PCP who is willing to order TRT-specific panels and may involve quarterly office visit co-pays.

The one assay mistake that costs men accurate results:
Always specify sensitive estradiol (LC-MS/MS method, sometimes labeled 'estradiol, sensitive' or 'estradiol LC/MS'). Standard estradiol immunoassays are calibrated for female reference ranges and are inaccurate at male levels — a standard assay showing 'normal' estradiol in a man on TRT may be meaningless. Many DTC services default to the standard assay; you must explicitly select the sensitive version. For provider comparison including lab quality, see best online TRT clinics compared 2026. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: men ordering standard estradiol immunoassay panels online, getting a falsely 'normal' reading, and making AI dosing decisions (or non-decisions) based on inaccurate data — either missing problematic E2 suppression or incorrectly believing their E2 is normal when it is not. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

The right TRT provider runs the right labs at the right intervals — and uses the results to optimize your protocol, not just renew your prescription. Use our provider comparison tool to find clinics that include monitoring labs, use sensitive estradiol assays, and have defined action thresholds for hematocrit, PSA, and testosterone levels.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

What blood work do I need before starting TRT?

The AUA guideline and Endocrine Society framework require at minimum: two separate morning total testosterone draws (both ≤300 ng/dL to confirm hypogonadism), CBC for baseline hematocrit, PSA (age ≥40), comprehensive metabolic panel, and lipid panel. Strongly recommended additions: LH and FSH (to determine primary vs secondary hypogonadism), sensitive estradiol, and SHBG. LH and FSH are particularly important — low LH with low T suggests secondary hypogonadism that may be reversible with enclomiphene rather than requiring lifelong TRT.

How often should I get labs on TRT?

For the first year: labs at baseline (before starting), at 3 months (first optimization check), and at 6–12 months. After the first year, on a stable protocol, annual labs are the standard minimum: total testosterone, estradiol, CBC/hematocrit, PSA, lipid panel, and CMP. More frequent testing (every 6 months) is appropriate if you have had hematocrit above 52%, are on anastrozole, or your protocol was changed within the last 6 months.

What testosterone level should I aim for on TRT?

The AUA therapeutic target is 350–750 ng/dL. Many men optimize symptoms between 500–700 ng/dL, though individual response varies. Critically, this range refers to a trough measurement (just before your next injection) for injectable TRT. A trough in this range means your average level throughout the cycle is meaningfully higher. Supraphysiologic levels >1,000–1,100 ng/dL at trough are associated with greater side effect risk without additional therapeutic benefit for most men.

Do I still need LH and FSH while on TRT?

No — not on established TRT. Exogenous testosterone suppresses LH and FSH to near-zero via negative feedback on the pituitary. This is expected and does not indicate a problem. Rechecking LH and FSH annually on TRT adds no clinical value. The time to check LH and FSH is before starting TRT (to confirm hypogonadism type) or if you are considering transitioning to enclomiphene or a SERM-based approach.

Why does the timing of my blood draw matter on TRT?

For injectable TRT, testosterone levels follow a curve: peak at 24–48 hours post-injection, then gradually decline to trough just before the next dose. Drawing at different points in this cycle gives radically different results — a peak draw on weekly injections might show 1,100 ng/dL, while a trough draw of the same protocol shows 450 ng/dL. Neither number is wrong — but they answer different questions. Standard practice: draw at trough (just before your next injection) for injection protocols to assess whether your minimum level is adequate.

What is a dangerous hematocrit on TRT?

The AUA and Endocrine Society consensus threshold is 54% — above this level, dose reduction is required. Values above 54% meaningfully increase blood viscosity and venous thromboembolism risk. Values approaching 58% require urgent clinical evaluation. The standard management cascade is: (1) dose reduction first, (2) injection frequency optimization (weekly vs biweekly) to reduce peaks, (3) therapeutic phlebotomy if dose reduction is insufficient, and (4) TRT discontinuation if polycythemia cannot be controlled.

How do I read my estradiol result on TRT?

Use a sensitive estradiol assay (LC-MS/MS method) for accurate results — standard immunoassays are unreliable at male estradiol levels. The optimal range for most men on TRT is 20–40 pg/mL. Both low AND high E2 cause symptoms: below 15 pg/mL causes joint pain, libido loss, and bone loss risk; consistently above 60–80 pg/mL with symptoms (gynecomastia, water retention, mood changes) warrants a protocol review — typically injection frequency optimization before reaching for anastrozole.

What PSA level should trigger concern on TRT?

The two most important PSA thresholds on TRT: (1) a rise of >1.4 ng/mL in any 12-month period (requires urology referral regardless of absolute PSA level), and (2) absolute PSA >4.0 ng/mL (requires urology workup). An initial PSA rise of 0.3–0.5 ng/mL in the first 3–6 months of TRT is expected and typically benign — testosterone reveals pre-existing PSA that was suppressed by low androgen levels. A rise larger than 0.5 ng/mL in the first 3 months warrants re-evaluation.

Can I order my own TRT labs without a doctor?

Yes — direct-to-consumer lab services (LabCorp on Demand, Ulta Lab Tests, Request A Test, Walk-In Lab) allow you to order and pay for blood work without a physician order. A full TRT monitoring panel (total T, sensitive E2, CBC, PSA, CMP) typically costs $150–$300 bundled. Key requirement: always specify the sensitive estradiol assay (LC-MS/MS method) — the standard immunoassay is inaccurate at male estradiol levels and will often produce misleading results.

What labs are NOT necessary to run regularly on TRT?

Labs that are not needed on established, stable TRT: LH and FSH (always near-zero on exogenous TRT — rechecking is wasteful), prolactin (unless new symptoms of a pituitary issue emerge), thyroid panel (follow standard PCP guidelines, not TRT-specific intervals), and DHT (tested routinely by some clinics but rarely clinically actionable for most TRT patients without specific hair loss or prostate concerns).